Standardization of iPSC quality by optimization of the peripheral blood reprogramming process.

Induced pluripotent stem cells (iPSC) have been key in advancing the development of next generation therapies for hard-to-treat conditions such as Parkinson’s disease, heart disease and cancer. These unique cells have the potential to become any cell of the body which accounts for their importance in the field of regenerative medicine. It is crucial to tightly control the manufacturing of iPSCs to generate safe and effective cell products at industrial scale. The goal of this project is to optimize the process of somatic cell reprogramming into iPSCs which will ultimately have an impact on the time and cost for delivering cell therapies to patients.

Faculty Supervisor:

David Knapp

Student:

Partner:

Stem Cell Network;BlueRock Therapeutics ULC

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Université de Montréal

Program: